High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines
Yangbing Zhao(Parker Institute for Cancer Immunotherapy), Richard A. Morgan(Sarepta Therapeutics (United States)), Steven M. Dunn(AXON Neuroscience (Slovakia)), Paul F. Robbins(National Cancer Institute), Alan Bennett(AXON Neuroscience (Slovakia)), Lawrence Yu(National Institutes of Health), Peter Molloy(AXON Neuroscience (Slovakia)), Steven A. Rosenberg(National Cancer Institute), Qiong J. Wang(National Institutes of Health), Yi Li(Yunnan Agricultural University), Zhili Zheng(Unknown), Bent K. Jakobsen(Mission Therapeutics (United Kingdom))
Cited by 216
Related Papers
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
|Journal of Clinical Oncology|2008|1.3k
IL-2: The First Effective Immunotherapy for Human Cancer
|The Journal of Immunology|2014|1.3k
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
|Journal of Clinical Investigation|2014|1.1k
Antimicrobial effect of surgical masks coated with nanoparticles
|Journal of Hospital Infection|2005|576
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
|The Journal of Experimental Medicine|1996|547